No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 12 | 15 | 109 | 28 | 43 | 54 | 197 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 1 | 2 | 46 | 2 | 6 | 7 | 106 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in Chennai, India, in 1992, California Software Company Limited delivers a comprehensive suite of services encompassing software development, IT infrastructure management, and business process outsourcing. The company specializes in crafting web, mobile, and IoT applications, alongside providing UI-UX design expertise and developing tailored point-of-sale platforms. To amplify online visibility and boost sales for enterprises, it offers a range of digital marketing solutions, including search engine optimization, app store optimization, social media marketing, and pay-per-click campaign management. Its proprietary product lineup features dSPEEDUp eCom, a versatile digital commerce platform supporting B2B, B2C, and C2C business models; dINSPIRA PoS, a point-of-sale system specifically designed for small retail operations; dBOT, an advanced conversational platform; and dULTIMA Omnichannel, which ensures a seamless and optimized consumer journey. Moreover, California Software provides several specialized solutions for the clinical and pharmaceutical industries. These include CS-CTMS, a configurable, cloud-based, end-to-end system for managing clinical trials; CS-eTrial, an electronic trial master file and remote monitoring platform for organizing, storing, and reviewing clinical trial documentation; CS-SAFETY, a regulatory-compliant, cloud-based pharmacovigilance and drug safety system; CS-CLIDAC, a dedicated clinical data warehouse and analytics console; and CS-RMS, a remote monitoring system for clinical trials.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
California Software Company Limited (CALSOFT.NS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in Chennai, India, in 1992, California Software Company Limited delivers a comprehensive suite of services encompassing software development, IT infrastructure management, and business process outsourcing. The company specializes in crafting web, mobile, and IoT applications, alongside providing UI-UX design expertise and developing tailored point-of-sale platforms. To amplify online visibility and boost sales for enterprises, it offers a range of digital marketing solutions, including search engine optimization, app store optimization, social media marketing, and pay-per-click campaign management. Its proprietary product lineup features dSPEEDUp eCom, a versatile digital commerce platform supporting B2B, B2C, and C2C business models; dINSPIRA PoS, a point-of-sale system specifically designed for small retail operations; dBOT, an advanced conversational platform; and dULTIMA Omnichannel, which ensures a seamless and optimized consumer journey. Moreover, California Software provides several specialized solutions for the clinical and pharmaceutical industries. These include CS-CTMS, a configurable, cloud-based, end-to-end system for managing clinical trials; CS-eTrial, an electronic trial master file and remote monitoring platform for organizing, storing, and reviewing clinical trial documentation; CS-SAFETY, a regulatory-compliant, cloud-based pharmacovigilance and drug safety system; CS-CLIDAC, a dedicated clinical data warehouse and analytics console; and CS-RMS, a remote monitoring system for clinical trials.